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We welcome Ebrahim and Clarke’s comments1 on the STROBE
Statement and are grateful for the opportunity to clarify some of
the issues they raise in their editorial. What is STROBE all
about? The STROBE Statement is a checklist of items that
should be addressed in articles reporting cohort studies,
case–control studies or cross-sectional studies, to STrengthen
the Reporting of OBservational studies in Epidemiology. A short
paper that presents the checklist and explains how it was
developed will be published in several journals2 in October 2007,
and will be freely available on the websites of these journals
(see www.strobe-statement.org for links to the paper). The
intention is to provide guidance on how to report observational
research well: the recommendations are not prescriptions for
designing or conducting studies—these decisions must be made
by investigators who know the subject matter. Also, while
clarity of reporting is a prerequisite to evaluation, the checklist
should not be seen as an instrument to evaluate the quality of
observational research. Good reporting does not necessarily
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mean good research. The importance of good reporting is that
others—readers, fellow scientists, reviewers and editors—can
form an informed opinion on whether the research was
appropriate and what aspects might need more scrutiny.
Yes, Ebrahim and Clarke are right: some of the recommenda-
tions included in STROBE are fairly basic. In this context, it is
important to define the audience for whom STROBE is
intended: the recommendations are predominantly aimed
at those who use epidemiologic study designs without
being expert epidemiologists. We think that they may well
outnumber experienced and well-trained research epidemiolo-
gists. For example, studies indexed with the Medical Subject
Heading ‘cohort studies’ in Medline are mainly published in
clinical specialist journals, and originate from clinical depart-
ments (Table 1). Fundamental deficiencies in reporting have
been identified for such journals. For example, a review of
survival analyses published in cancer journals found that
almost half of articles did not give any summary of length of
follow-up.3 But the problem is not restricted to clinical
specialist journals: a survey of recent practice in the reporting
of epidemiological research4,5 included all major epidemiologi-
cal and general medical journals and found, for example, that
few investigators explained their choice of confounding vari-
ables. Asking investigators to ‘Make clear which confounders were
adjusted for and why they were included’ might thus not only be
pertinent to the example of folic acid and the risk of stroke
mentioned by Ebrahim and Clarke, but an important issue in
many other reports of epidemiological studies. So, although this
and other STROBE recommendations ‘might be found in an
epidemiology text targeted at Masters students in the first term
of their first year’1 they are sorely needed to improve the
reporting of epidemiological research.
In addition to the short paper mentioned earlier, a detailed
companion paper, the STROBE Explanation and Elaboration
article, justifies the inclusion of the different checklist items and
gives methodological background and published examples of
what we consider transparent reporting. This explanatory paper,6
which will be published (also with immediate open access) in
Epidemiology, and electronically in PLoS Medicine and Annals of
Internal Medicine, is an integral part of STROBE. Some of the
examples we used in the explanatory paper came from studies of
lower methodological quality, whose results were never repli-
cated—yet some aspects of the study were clearly reported.
Again, good reporting does not necessarily mean good research.
We strongly recommend using the STROBE checklist in
conjunction with the explanatory article.6 Indeed, this article
addresses many of the points raised by Ebrahim and Clarke.1
For example, they fear that investigators seeking guidance
might be confused when asked to ‘Explain the scientific
background and rationale for the investigation being reported’, because
in some studies the original rationale for the study might have
been very different from the purpose of the analysis the
investigators aim to publish today. We explicitly address this
situation in the explanatory paper, and advise authors to briefly
restate the original aims of the study: this might help readers
understand the context of the research and possible limitations
in the data. We stress that the secondary use of existing data
is a creative part of observational research and does not
necessarily make results less credible or less important. For
example, the Physicians’ Health Study, a randomized controlled
trial of aspirin and carotene, was later used to confirm that a
point mutation in the factor V gene was associated with an
increased risk of venous thrombosis, but not myocardial
infarction or stroke.7
STROBE asks authors to ‘Give a cautious overall interpretation of
results, considering objectives, limitations, multiplicity of analyses,
results from similar studies, and other relevant evidence’, in line with
Richard Doll’s important statement (cited by Ebrahim and
Clarke1) on the need to confirm unexpected results with
potential implications for public health in further studies. The
need for replication, which is an important point in science in
general,8 is well taken, but has little to do with good reporting
of an individual study: it is not the responsibility of the
scientists who report that study. Nevertheless, in the explana-
tory paper,6 we discuss the scope of observational studies, from
reporting a first hint of a potential cause of a disease, to
verifying the magnitude of previously reported associations and
Table 1 Journals that published the 100 most recent articles indexed in
Medline as ‘cohort studies’, August 2007
Acta Derm Venereol (1) J Hum Genet (1)
Acta Myol (1) J Hypertens (3)
Am J Health Syst Pharm (1) J Infect (1)
Am J Transplant (1) J Korean Med Sci (2)
Arch Bronconeumol (2) J Neurosurg (1)
Arch Phys Med Rehabil (1) J Neurovirol (1)
Arch Surg (5) J Nutr (1)
Arterioscler Thromb Vasc Biol (4) J Oral Sci (1)
Asian J Surg (2) J Prosthet Dent (1)
BJOG (1) J Surg Oncol (2)
BMC Genet (1) J Surg Res (1)
Can J Gastroenterol (1) Lancet (1)
Can Respir J (1) Lung Cancer (3)
Cancer Causes Control (3) Med J Aust (1)
Circulation (1) Methods Mol Biol (1)
Clin Implant Dent Relat Res (1) Mol Med (1)
Clin Nephrol (1) Nephrol Dial Transplant (2)
Clin Ther (1) Neurosurgery (1)
Community Dent Health (3) Nord J Psychiatry (2)
Curr Diab Rep (1) Otolaryngol Head Neck Surg (1)
Epidemiology (3) Pediatr Infect Dis J (1)
Eur J Cardiothorac Surg (2) Phys Med Biol (1)
Eur J Clin Pharmacol (1) Psychiatr Serv (1)
Eur J Nucl Med Mol Imaging (1) Respir Res (1)
Haematologica (1) Rev Invest Clin (1)
Heart Surg Forum (3) Rev Med Chir Soc Med Nat Iasi (1)
Hypertension (9) Spine (2)
Int J Technol Assess Health Care (1) Stat Med (1)
J Am Coll Cardiol (6) World J Urol (1)
J Fam Pract (2)
The figures in brackets indicate the number of publications.
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stress that further studies to confirm or refute initial observa-
tions are often needed.9 STROBE tries to accommodate these
diverse uses of observational research—from discovery to
refutation or confirmation.
As the great mathematician, physicist and philosopher Jules
Henri Poincare´ (1854–1912) said: ‘Science is built up of facts,
as a house is built of bricks; but an accumulation of facts is no
more a science than a heap of bricks is a house.’10 Does this
mean authors should be asked to ‘conduct a systematic review
of other similar studies’?1 As a previous editorial in the
International Journal of Epidemiology argued,11 systematic reviews
should be seen as original research and be published as such,
rather than be reported in a paragraph of a discussion section.
Interestingly, The Lancet recently updated their policy, asking
authors of randomized trials to illustrate the relation between
existing and new evidence by referring to a systematic review
and meta-analysis.12 We believe that in many situations this
requirement is also appropriate for reports of observational
research. But note that both The Lancet and the CONSORT
recommendations for the reporting of randomized trials
(Consolidated Standards of Reporting Trials)13 stop short of
asking authors to do a systematic review and meta-analysis.
Contrary to Ebrahim and Clarke’s assertion, we do not think
that observational studies are ‘largely incapable of making
definitive conclusions on the basis of robust findings’1: there
are situations where observational research is as valid, more
appropriate and more informative than randomized trials.14–17
Observational research is important and often hugely
successful—much of health care and public health depends
on it, from genetics to infectious diseases, from environmental
exposures to the prognostic stratification of patients. However,
like all research, in all branches of science, results need
informed, critical discussion and such discussion is only
possible if authors report transparently what was done and
why it was done. We share Ebrahim and Clarke’s optimism that
STROBE will make an important contribution to improving the
quality of reporting of observational research. Finally, we stress
that STROBE and other recommendations on the reporting of
research should be seen as evolving documents that require
continual assessment, refinement, and, if necessary, change.18
We will revise the checklist in the future, taking into account
criticism,1 new evidence, and experience from its use. We invite
readers to submit their comments via the STROBE website
(www.strobe-statement.org).
The authors are members of the STROBE group.
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